thymoma
Conditions
Interventions
test group:Famciclovir antiviral treatment during perioperative period
Control group:Routine treatment of perioperative period
Sponsors
Tianjin Medical University affiliated General Hospital
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1. Patients who have been diagnosed with myasthenia gravis (MG) by visiting a doctor in the research center, assessed by a neurologist, meeting the diagnostic criteria of the 2015 version of the Chinese guidelines for the diagnosis and treatment of myasthenia gravis; 2. On the basis of typical clinical features of MG, with pharmacological features and/or neuroelectrophysiological features, excluding other diagnoses, MG can be diagnosed clinically; 3. Thymus imaging (CT and MR) consider thymic thymus tumor; 4. From July 2021 to July 2022, receive basic treatment (cholinesterase inhibitor, adrenocortical hormone, etc.) in the thoracic surgery department of the research center and randomize antiviral/placebo treatment; 5. Subjects voluntarily join this study, agree to collect relevant information including hematological testing information, and sign the informed consent form (patients under the age of 18 should be signed by their legal representatives).
Exclusion criteria
Exclusion criteria: 1. Accompanied by serious underlying diseases, such as liver and kidney failure, heart failure, etc.; 2. Patients with other systemic tumors; 3. Evaluation of the prognosis of the impact of mental illness; 4. According to the judgment of the investigator, there are other patients with concomitant diseases that seriously endanger the safety of the patient or affect the completion of the study; 5. The investigator assesses those who are expected to have poor compliance.
Design outcomes
Secondary
| Measure | Time frame |
|---|---|
| Hospitalization time due to myasthenia gravis within 3 years after enrollment (days);Myasthenia gravis activity of daily living score;Proportion of participants who reached the lowest performance status;Whether to use non-glucocorticoid immunosuppressive agents, plasma exchange, intravenous use of gamma globulin; | — |
Primary
| Measure | Time frame |
|---|---|
| time-weighted averaged Quantitative Myasthenia Gravis score;time-weighted average required dose of prednisone;immunizational funtional test;Flow cytometry; | — |
Countries
China
Contacts
Public ContactZhang Peng
Tianjin Medical University affliated General Hospital
Outcome results
None listed